BioSpace News Archive

August Bioservices, LLC today announced that it secured $65 million in Series B funding led by Oak HC/FT, who led the Series A in July 2020.

Salix Pharmaceuticals today announced the launch of a series of social media and digital initiatives to raise awareness during Constipation Awareness Month in December.

Eisai announced today that new study results on its in-house discovered and developed anticancer agent eribulin mesylate (HALAVEN ® , “eribulin”) will be presented during the 2022 San Antonio Breast Cancer Symposium (SABCS), which is taking place virtually and in-person in San Antonio, Texas from December 6-10.

Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that, following the recent receipt of official minutes from its pre-NDA (New Drug Application) meeting with the U.S. Food and Drug Administration (FDA), the Company plans to submit an NDA as soon as the end of 2022 for marketing approval of the investigational drug candidate ADX-2191 for the treatment of primary vitreoretinal lymphoma.

Hologic Ranked #1 for Mammography System Performance and Customer Satisfaction for 10th Consecutive Year.

Vaxart, Inc. (Nasdaq: VXRT) today announced it will commence a new study of Vaxart’s oral pill norovirus vaccine candidate focused on protecting breastfeeding mothers and their infants.

Integra LifeSciences Holding Corporation (NASDAQ:IART), a leading global medical technology company, today announced that it entered into a definitive agreement to acquire Surgical Innovation Associates (SIA), which develops, markets and sells DuraSorb®, a resorbable synthetic matrix for plastic and reconstructive surgery.

Opus Genetics, a patient-first, clinical-stage gene therapy company developing treatments for inherited retinal diseases, today announced the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a Phase 1/2, first-in-human clinical trial of OPGx-001 in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5).

WishBone Medical, Inc., a leader in pediatric orthopedic medical devices, announced the procurement of additional growth capital as well as changes to executive leadership, including the appointment of Dr. Mark Figgie as Interim Chief Executive Officer.

Hoffmann-La Roche Limited (Roche Canada) announced today that it has signed agreements with the Government of Canada to supply 15,000 treatment courses of ACTEMRA ® IV (tocilizumab for injection) for adult patients hospitalized with COVID-19.